Free Trial
NASDAQ:IXHL

Incannex Healthcare (IXHL) Stock Price, News & Analysis

Incannex Healthcare logo
$2.59
+0.32 (+14.10%)
(As of 11/1/2024 ET)

About Incannex Healthcare Stock (NASDAQ:IXHL)

Key Stats

Today's Range
$2.20
$2.73
50-Day Range
$1.56
$2.59
52-Week Range
$0.80
$12.68
Volume
141,427 shs
Average Volume
114,547 shs
Market Capitalization
$164.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Incannex Healthcare Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
20th Percentile Overall Score

IXHL MarketRank™: 

Incannex Healthcare scored higher than 20% of companies evaluated by MarketBeat, and ranked 899th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Book Value per Share Ratio

    Incannex Healthcare has a P/B Ratio of 14.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.53% of the float of Incannex Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Incannex Healthcare has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incannex Healthcare has recently decreased by 27.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Incannex Healthcare does not currently pay a dividend.

  • Dividend Growth

    Incannex Healthcare does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.53% of the float of Incannex Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Incannex Healthcare has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incannex Healthcare has recently decreased by 27.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Incannex Healthcare has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Incannex Healthcare this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.64% of the stock of Incannex Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.43% of the stock of Incannex Healthcare is held by institutions.

  • Read more about Incannex Healthcare's insider trading history.
Receive IXHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incannex Healthcare and its competitors with MarketBeat's FREE daily newsletter.

IXHL Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

IXHL Stock Analysis - Frequently Asked Questions

Incannex Healthcare's stock was trading at $4.64 at the beginning of 2024. Since then, IXHL shares have decreased by 44.2% and is now trading at $2.59.
View the best growth stocks for 2024 here
.

Incannex Healthcare Inc. (NASDAQ:IXHL) announced its quarterly earnings data on Monday, September, 30th. The company reported ($0.39) earnings per share (EPS) for the quarter. The company earned $0.01 million during the quarter.

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

Last Earnings
9/30/2024
Today
11/02/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IXHL
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
16,441.32
Book Value
$0.18 per share

Miscellaneous

Free Float
54,187,000
Market Cap
$164.41 million
Optionable
Not Optionable
Beta
8.15
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:IXHL) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners